1Cuschieri A, Fayers P, Fielding J, et al. PostoPerative morbid- ity and mortality after DlandD2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative GrouP[J]. Lancet, 1996,347 (0007) :995 - 999.
2Bonenkamp J J, Hermans J, Sasako M, et al. Extended lymph node dissection for gastric cancer[J]. N Enel J Med, 1999,340 (12) :905- 914.
4Wilke H,Preusser P,Fink U,et al.Preoperative chemotherapy in locally advanced and nonresectable gastric cancer:a phase Ⅱ study with etoposide,doxorubicin,and cisplatin.J Clin Oncol,1989,7:1318-1326.
5Fujimura T,Yonemura Y,Muraoka K,et al.Continuous hyperthermic perthrmic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer.Randomized controlled study.World J Surg,1994,18:150 155.
6Nakazato H,Koike A,Saji S,et al.Efficacy of immunoche motherapy as adjuvant treatment after curative resection of gastric cancer.Lancet,1994,343:1122-1126.
8Setala LP,kosma VM,Marin S,et al.Prognostic factors in gastric cancer:the value of vascular invasion,mitotic rate and lymphoplasmacytic infiltration.Br J Cancer,1996,74:766-772.
9Roukos DH,Lorenz M,Encke A,et al.Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept:a prospective long term follow up study.Surgery,1998,123:573-578.
10Manzoni G,Verlato G,Guglielmi A,et al.Prognostic significance of lymph node dissection in gastric cancer.Br J Surg,1996,83:1604-1607.
4Cappellani A,Zanghi A,Di Vita M,et al.Clinical and biologi-cal markers in gastric cancer:update and perspectives[J].FrontBiosci,2010,2:403-412.
5Bain GH,Petty RD.Predicting response to treatment in gas-troesophageal junction adenocarcinomas:combining clinical,im-aging,and molecular biomarkers[J].Oncologist,2010,15(3):270-284.
6Wang Y,Hewitt S M,Liu S,et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellu- lar localisation of beta-eatenin in ovarian tumours[J. Br J Canc- er, 2006,94(5) : 686-691.
7Wang Y,Liu S,Zhu H,et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous ceil carcinoma[Jj. Int J Cancer,2008,123(3):561 568.
8Saitoh T, Katoh M. FRAT 1 and FRAT 2, clustered in human chro- mosome 10@4.1 region,are up-regulated in gastric cancer-J. Int J Oncol, 2001,19(2) :311-315.
9Jonkers J,Korswagen HC,Acton D. Activation of a novel proto oncogene, Fratl, contributes to progression of mouse T cell [ym- phomas EJ. EMBOJ,1997,16(3):441-450.
10Jonkers J, Weening J J, van der valk M. Overexpressionof Fratl in transgenie mice leads to glomeruloselerosis and nephritic syndrome, and provides direct evidence {or the involvement o{ Fratl in lympho- ma-progressionEJ. Oncogene,1999,18(44) :5982-5990.
